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Exome and genome sequencing of nasopharynx
cancer identiﬁes NF-kB pathway activating
mutations
Yvonne Y. Li1,*, Grace T.Y. Chung2,*, Vivian W.Y. Lui3,4,*, Ka-Fai To2, Brigette B.Y. Ma5, Chit Chow2,
John K.S. Woo6, Kevin Y. Yip7, Jeongsun Seo8, Edwin P. Hui5, Michael K.F. Mak2, Maria Rusan1, Nicole G. Chau1,
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Nasopharyngeal carcinoma (NPC) is an aggressive head and neck cancer characterized by
Epstein-Barr virus (EBV) infection and dense lymphocyte inﬁltration. The scarcity of NPC
genomic data hinders the understanding of NPC biology, disease progression and rational
therapy design. Here we performed whole-exome sequencing (WES) on 111 micro-dissected
EBV-positive NPCs, with 15 cases subjected to further whole-genome sequencing (WGS), to
determine its mutational landscape. We identiﬁed enrichment for genomic aberrations of
multiple negative regulators of the NF-kB pathway, including CYLD, TRAF3, NFKBIA and NLRC5, in
a total of 41% of cases. Functional analysis conﬁrmed inactivating CYLD mutations as drivers for
NPC cell growth. The EBV oncoprotein latent membrane protein 1 (LMP1) functions to con-
stitutively activate NF-kB signalling, and we observed mutual exclusivity among tumours with
somatic NF-kB pathway aberrations and LMP1-overexpression, suggesting that NF-kB activation
is selected for by both somatic and viral events during NPC pathogenesis.
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N
asopharyngeal carcinoma (NPC) is one of the most
aggressive head and neck cancers and frequently
metastasizes to distant lymph nodes and organs1,2. Its
distinct etiology linked with latent infection of the oncogenic
Epstein-Barr virus (EBV) and characteristic heavy lymphocyte
inﬁltration often distinguish NPC from other head and neck
cancers. In fact, EBV-associated NPC is endemic in Southern
China and Southeast Asia, contrasting with the epidemic Human
Papillomavirus (HPV)-associated head and neck cancer in
some Western countries. Due to the intrinsic invasiveness and
asymptomatic nature of the disease, majority of NPC patients
are diagnosed with advanced diseases (60–70% cases) with
poor outcome. Thus far, there is no effective targeted therapy
for advanced NPC.
NPC is a complex malignancy with etiology and pathology
involving both EBV infection and a combination of multiple
genetic aberrations. Unlike other head and neck cancers, the
scarcity of NPC genomic data to date hinders the understanding
of NPC biology, disease progression and rational therapy design
for better treatments. The extensive stromal components of these
often small-sized tumours present major challenges for compre-
hensive and precise genomic characterization.
Here we report the genomic landscape of the ﬁrst and largest
cohort of microdissected EBV-positive NPC of more than 100
cases. Our study suggests that the somatic mutation rate of NPC
is substantially higher than that reported previously3 and reveals
that majority of NPCs display activation of the NF-kB signalling
pathway as a result of somatic inactivating mutations in negative
regulators of NF-kB.
Results
Whole-exome sequencing (WES) of microdissected NPC. WES
was performed on 111 unique tumour specimens derived from 105
unique subjects. The cohort included 78 primary tumours, 11 local
recurrences and 22 metastatic tumours. Ninety-seven subjects were
from Southeast Asia where NPC is endemic and eight from the
United States (Supplementary Table 1 and Supplementary Data 1).
The overall non-synonymous mutation rate of EBV-positive NPC
was signiﬁcantly lower than that of HPV-positive head and neck
squamous cell carcinoma (HNSCC)4 and EBV-positive stomach
adenocarcinoma1 (P¼ 0.0196 and 0.0004, respectively; unpaired
t-test; Fig. 1a). Primary, recurrent and metastatic NPC tumours
shared a similar mutational burden in our cohort and orthogonal
validation of mutations by amplicon sequencing demonstrated a
validation rate of 82% at selected sites. Interestingly, increasing
mutational burden in primary NPC lesions (N¼ 70) was negatively
correlated with overall and disease-free survival (P¼ 0.0214 and
0.0118, respectively; Log-rank test; Fig. 1b). NPC mutational rate
was not associated with age, sex or clinical stage.
The combination of EBV infection, diet and genetic factors are
etiologically linked with NPC pathogenesis in endemic regions5.
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Figure 1 | Somatic mutation rates and mutational signatures of NPC tumours identiﬁed by WES. (a) NPC tumours have signiﬁcantly lower rate of non-
synonymous mutations as compared with HPV-positive HNSCC and EBV-positive stomach adenocarcinoma (TCGA, USA). (b) The mutational burden,
stratiﬁed by the top, mid and low quartile counts per patient, correlated with overall and disease-free survival in NPC patients (N¼ 70 NPC patients with
primary tumours). (c) Mutation signatures of 70 primary and 27 recurrent or metastatic NPC cases reveal a primarily C to T transition signature. (d) The
top COSMIC cancer mutation signatures in NPC.
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To identify whether mutagenic processes are operative in NPC,
we analysed the mutation spectrum of NPC. The predominant
type of substitution was C4T transition at NpCpG sites in both
primary and recurrent/metastatic tumours (Fig. 1c). Combined
non-negative matrix factorization clustering and correlation with
the 30 curated mutational signatures deﬁned by the Catalog of
Somatic Mutations in Cancer (COSMIC) database6,7 revealed
three dominant signatures in NPC (Supplementary Data 2).
The predominant signature underlies the deamination of
5-methyl-cytosine process (Signature 1), followed by defective
DNA mismatch repair signature (Signatures 6þ 15þ 20þ 26),
and by an APOBEC/AID signature, which was only observed in a
subset of primary NPCs (Signatures 2þ 13) (Fig. 1d).
Negative regulators of NF-jB pathway are commonly mutated.
To identify somatically mutated genes in NPC, we employed the
MutsigCV 2.0 algorithm8 with a Benjamini-Hochberg false
discovery (FDR) threshold of 0.1 (Figs 2 and 3a). We identiﬁed
a total of seven genes signiﬁcantly mutated above background
rates in Asian NPCs: TP53, NRAS, NF-kB pathway genes, CYLD,
TRAF3 and NFKBIA, the major histocompatibility complex
(MHC) class I gene HLA-A, and the transcriptional regulator
MED12L, a gene previously reported to be mutated in mouse and
human HNSCC9 (Supplementary Data 3 and 4). TP53 mutations
were observed in 9.5% of cases, consistent with rates reported
previously1,4. Yet, TP53 mutations were B2.3-fold enriched in
recurrent/metastatic NPC (15.2%; versus 6.4% in primary NPC),
perhaps due to therapy-related selection. TP53 mutation status
was not correlated with survival of patients with primary NPC.
Our US cohort size was not large enough to enable statistically
robust comparisons with the Asian cohort of signiﬁcantly
mutated genes.
CYLD, TRAF3 and NFKBIA are important negative regulators
of NF-kB activity. CYLD is a tumour suppressor gene that
deubiquitinates TRAF2, an activator of NF-kB signalling10,11.
Germline mutations in CYLD are associated with familial
cylindromatosis, characterized by multiple benign tumours in
the head and neck region and hair follicles12. We found that the
majority of CYLD mutations (8/11 mutations; 72.7%) were
truncating, including nonsense and frameshift mutations.
Truncating mutations of CYLD have not been identiﬁed in
NPC previously, but were found at lower rates in HNSCC4.
TRAF3, a key negative regulator of the non-canonical NF-kB
pathway in NPC, was found to be mutated in 8.6% cases (9/105
cases), a rate higher than previously reported in NPC (1/33 cases;
3.0%) (refs 13,14). Most NPC-associated TRAF3 mutations were
located in the RING ﬁnger and the MATH/TRAF domains
(Fig. 3a), regions known to be essential for the suppression of
NIK-activating NF-kB signalling13. Thus, mutations at these sites
may lead to constitutive activation of NF-kB signals in NPC
tumours. NFKBIA functions to trap NF-kB in the cytosol, thus
inhibiting its activation, and was mutated in 6.7% of NPC.
Deletion of this gene has been reported in glioblastoma, which
was associated with poor survival15.
Additional genes which displayed recurrent mutations in our
data set but did not reach statistical signiﬁcance (qo0.1) included
the NF-kB pathway member NLRC5, which was mutated in six
cases (4.8%) (Fig. 3a). NLRC5 is a potent inhibitor of NF-kB
activation and Type I interferon signalling16. It competes with
NEMO for binding to IKK-alpha and IKK-beta, thus blocking
their activation and kinase activities. Notably, NLRC5, is also a
key transcriptional activator of MHC class I genes, including
HLA-A and HLA-B. In fact, HLA-A was signiﬁcantly mutated in
our cohort (7.2% of cases), with predominantly recurrent
truncating mutations. These ﬁndings implies that inactivation
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of MHC class I molecules may have a role in the pathogenesis of a
subgroup of NPC.
Mutations in PI3K/MAPK pathways and chromatin mod-
iﬁcation. Recurrent mutations in PI3K/MAPK pathway activators
or regulators (PIK3CA, PTEN, ERBB3, BRAF1, NF1, FGFR2,
FGFR3) and chromatin modifying enzymes (KMT2D, KMT2C,
EP300, KDM5A) were also observed, but infrequently, in agreement
with a previous study3 (Fig. 3a,b, Supplementary Fig. 1).
Interestingly, recurrent mutations of genes previously reported to
be mutated in cancer: ABL1, BUB1B, NCOR1 (each mutated in
three tumours), and CARS, HSP90AB1, NCOA1 (each mutated in
two tumours) were uniquely found in recurrent/metastatic NPCs
(n¼ 33). Among these, ABL1 K690del was identiﬁed in a NPC liver
metastasis (HKNPC-091) and a lymph node metastasis (P-10-
27817). This ABL1 mutation has been identiﬁed in melanoma by
the TCGA (www.cbioportal.org). We identiﬁed two individual’s
tumours with hypermutator phenotypes (HKNPC-003, HKNPC-
033) with 2,051 and 817 somatic mutations in coding regions,
respectively (Fig. 2); both tumours harboured mutations of
mismatch repair genes, including MSH6 (HKNPC-003) and
MLH1 (HKNPC-033). Both patients with hypermutated tumours
had poor overall survival of B12 and 19 months, respectively.
Clonal expansion in NPC recurrences and metastases. Multiple
tumours were available from four patients for clonality analyses
by comparing variant frequencies between the primary and
respective recurrent/metastatic lesions from the same individual
(Supplementary Fig. 2, Supplementary Data 5). Surprisingly, we
noted that many mutations with previously annotated roles in
cancer were not shared between the paired primary and recurrent
lesions. This observation from our two primary/recurrent tumour
pairs (cases HKNPC001 and HKNPC012) seems to concur with
our recent ﬁndings in primary/recurrent HNSCC. In paired pri-
mary/recurrent HNSCC samples, we also found that TP53 was
the only shared annotated mutated cancer gene as deﬁned
by the Cancer Gene Census, COSMIC17. For these NPC patients,
the recurrent or metastatic lesion appeared to show a single-
nucleotide variant (SNV) clonality distribution different from
that of the primary tumour, supportive of emerging new
subclone(s) in recurrences. On the other hand, the liver
metastases from patients HKNPC-008 and HKNPC-009 both
showed a relatively higher percentage of shared mutations among
two distinct regions of liver metastases (Supplementary Fig. 3;
Supplementary Data 5).
Frequent chromosomal deletions of Chr 3p, 14q and 16q.
Regions of somatic copy number alteration were deﬁned using
WES and whole-genome sequencing (WGS) segmentation data
and the GISTIC tool18 (Fig. 4; Supplementary Figs 4 and 5).
Similar gene copy changes were observed in our WES (from
formalin-ﬁxed parafﬁn-embedded (FFPE) tissues) and WGS
(from fresh frozen tissues) studies. Selected copy number
variants (CNVs) were further validated and conﬁrmed by
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Figure 3 | Recurrent somatic mutations in NPC. (a) Mapping of mutation sites of CYLD, TRAF3, NFKBIA, NLRC5, TP53, HLA-A, MED12L, NRAS and PIK3CA
from this NPC cohort. Functional domains of the altered proteins are based on UniProt database. (b) Non-synonymous mutations in chromatin remodelling
genes and PI3K/MAPK activating genes in NPC. Primary NPCs are shown in light blue boxes, local recurrent and metastatic tumours in pink and green
boxes, respectively.
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ﬂuorescence in situ hybridization (FISH) analyses
(Supplementary Fig. 6). Arm-level copy number analysis
demonstrated consistent losses of 3p, 14q, 16q and recurrent
12p ampliﬁcation. As we reported previously, 3p loss contributes
to the inactivation of multiple NPC-related tumour suppressors
including RASSF1A and FHIT3,19. Losses of 14q and 16q may
serve as one of the mechanisms for inactivating multiple negative
regulators of NF-kB pathway, such as NFKBIA (14q13), TRAF3
(14q32.3), CYLD (16q12.1) and NLRC5 (16q13). Notably,
deletion of CYLD was identiﬁed in 20/97 cases (20.6%) with
one case harbouring homozygous deletion (Supplementary
Fig. 5). The CYLD homozygous deletion was further conﬁrmed
by FISH (Supplementary Fig. 7). Other recurrent focal copy
number peaks included loss of the CDKN2A/CDKN2B locus
(9p21.3; 57.6%), consistent with our previous ﬁndings20.
CYLD is tumour-suppressive in NPC. To further deﬁne the
scope of genetic alterations in NF-kB signalling at the whole-
genome level, we determined the structural variants from 15
whole-genome sequenced Asian NPC tumours (Supplementary
Data 6). We also performed FISH analyses for CYLD, TRAF3 and
NFKBIA in all Asian NPCs. For both CYLD and TRAF3, inacti-
vating structural alterations, including translocation, tandem
duplication and homozygous deletion, were identiﬁed in seven
additional cases (Fig. 5a,b; Supplementary Figs 7 and 8). No
additional cases with NFKBIA structural alteration were identi-
ﬁed. The summative rate of somatic genetic events in CYLD
(18.6%) and TRAF3 (17.5%) was as high as B35.1% (with one
case having both CYLD and TRAF3 alterations), suggesting that
CYLD and TRAF3 genomic aberrations may represent a major
mechanism underlying NPC tumorigenesis.
We and others have previously reported cellular studies of
TRAF3 in NPC models14. Here we further showed that wild type
TRAF3, but not the patient-derived mutants inhibited the
non-canonical NF-kB pathway in NPC cells (Supplementary
Fig. 9). On the other hand, little is known about the functional
importance of CYLD mutations in NPC or other cancers.
Importantly, a CYLD frameshift mutation was also identiﬁed in
the EBV-positive NPC cell line, C666-1, resulting in complete loss
of CYLD protein expression in this cell model (Supplementary
Fig. 10). Ectopic expression of CYLD wild-type gene suppressed
C666-1 cell proliferation (Fig. 5c) and anchorage-independent
growth on soft agar (Fig. 5d), while expression of patient-derived
CYLD point and truncating mutations resulted in the loss of these
tumour-suppressive activities (Fig. 5c,d). This loss-of-function
activity of CYLD mutants was conﬁrmed in another NPC cell
line, HK1-EBV (Supplementary Fig. 11). Further, a higher NF-kB
transcriptional activity (as measured by an NF-kB-luciferase
reporter assay) was observed in C666-1 cells expressing the
patient-derived CYLD mutants versus wild-type (Fig. 5e).
Furthermore, nuclear translocation of Bcl-3, a component of
reported NPC-associated activated NF-kB signal p50/p50/Bcl-3
(ref. 14), was inhibited upon CYLD WT expression, but not by
CYLD mutants (Supplementary Fig. 12).
LMP1 and NF-jB pathway aberrations are mutually exclusive.
The viral oncoprotein, LMP1 is a potent activator of NF-kB
signalling in NPC21. We detected high LMP1 expression in 25.7%
of cases by immunohistochemistry and high LMP expression was
associated with poor outcome, as previously reported22. We
identiﬁed mutual exclusivity among LMP1 overexpression and
NF-kB pathway aberrations dominated by CYLD, TRAF3, NFKBI
and NLRC5 events (Fig. 6; Supplementary Fig. 13). Speciﬁcally,
genomic alterations in NF-kB pathway regulators were exclusive
with high LMP1 expression (P¼ 0.00014; Fisher’s exact test,
two-tailed), further supporting NF-kB deregulation via somatic
genetic events as a core feature of NPC. Our ﬁndings provide a
potential genetic explanation for the unique inﬂammatory
feature of NPC, contributed by both somatic and viral-
mediated addiction to NF-kB signalling in this EBV-associated
malignancy2,5.
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Poor outcome for patients with MHC class I aberrations. In
addition to NF-kB pathway alterations, we also noted a high rate
of MHC class I gene aberrations (NLRC5, HLA-A, HLA-B, HLA-
C, B2M). Frequent rearrangements of HLA-A, HLA-B and HLA-C
genes were identiﬁed by dRanger analysis23 (Supplementary Data
7). Twenty-nine NPC cases (30%) were MHC class I-altered
(rearrangements and point mutations) (Fig. 7a). Importantly,
survival analysis identiﬁed inferior outcome in these MHC class
I-altered patients with primary NPC (Fig. 7b). It is likely that the
deﬁciency of antigen presentation mechanism may represent an
escape mechanism from host immunosurveillance, thus favouring
rapid tumour progression. The clinical efﬁcacy of immune
checkpoint inhibitors in this genetic subgroup of NPC patients
should be examined carefully as these drugs often rely on intact
tumour antigen presentation in situ.
Given a prior report of an association among ERBB/PI3K
activation and inferior outcome in NPC3, we assessed whether we
could conﬁrm this ﬁnding in our cohort. We noted no signiﬁcant
difference in outcome among cases with and without known
activating mutations in these oncogenic pathways among our
primary set of 70 tumours (Supplementary Fig. 14). We did,
however, note that mutations in genes known to activate PI3K
signalling were non-statistically enriched in recurrent/metastatic
cases and found that there was an association between PI3K
activating events and poor outcome among recurrent and
metastatic NPC patients (Supplementary Fig. 14), in accordance
with data presented in HNSCC24. This ﬁnding could have
therapeutic implications in that targeted kinase inhibitors are
often explored initially in the recurrent/metastatic setting.
Somatically altered pathways of NPC. To better deﬁne somati-
cally altered pathways in NPC, we mapped all somatic variants
identiﬁed in our mutational and copy number analyses to known
functional annotations with selected genes, and summarized as a
pathway diagram for NPC (Fig. 8). As noted above, frequent
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somatic alterations in key nodes of the NF-kB pathways were the
dominant feature in our NPC cohort, and we also observed
recurrent somatic alterations in genes regulating cell cycle pro-
gression, chromatin remodelling and DNA repair. Notably, few
variants which have previously been associated with response to a
targeted therapeutic agent were identiﬁed, although recurrent
mutations and ampliﬁcations of RAS family genes and PI3K/
mTOR pathway members were observed.
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Figure 6 | Genomic aberrations in NF-jB pathways in NPC. Mutual exclusivity between LMP1 overexpression and NF-kB somatic alterations in NPC
tumours (P¼0.00014). LMP1 staining of representative tumours are also shown.
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Figure 7 | Genomic aberrations of MHC class I genes in NPC. (a) A summary of genetic alterations in MHC class I genes, including HLA-A, HLA-B, B2M
and NLRC5. (b) NPC patients with MHC class I gene mutations have poorer overall survival and disease-free survival (P¼0.003, and Po0.0001,
respectively; Log-rank test on 70 primary NPC cases).
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Discussions
In summary, our study of over 100 micro-dissected NPCs using
WES, WGS and FISH revealed a higher degree of somatic
mutation and structural variation (SV) in NPC than was
previously recognized and enabled the discovery of several novel
genomic events that facilitate NPC tumorigenesis, principal
among these being NF-kB pathway activation in NPCs with
low LMP1 expression. We provide the most comprehensive view
of NPC genomics reported to date and identify key somatically
altered pathways in this disease including novel mechanisms of
NF-kB activation. This study also reveals that NF-kB deregula-
tion, either via somatic genetic events or LMP1 overexpression, is
a core feature of NPC. We also demonstrated how NPC genomics
can potentially inform therapy, highlighting the importance of
targeting activated NF-kB signalling in NPC patients with
somatic defects in NF-kB negative regulators. As shown in our
previous study, knockdown of NF-kB signals by short interfering
RNAs can effectively inhibit NPC growth and survival14. It can be
envisioned that NF-kB inhibitors and the newly developed small
molecule inhibitors targeting Bcl3 can potentially be used as novel
therapeutics for NPC patients25,26. Furthermore, the discovery of
MHC class I lesions in a subgroup of NPC may have biological
implications for immune checkpoint inhibitors or other cytotoxic
T-cell-based immunotherapies in NPC.
In conclusion, our study suggests that NPCs sub-classiﬁed by
LMP1 status are distinct in terms of clinical history and outcome
as well as genomic features. Future laboratory studies and
precision medicine-based treatment approaches for NPC would
need to consider the features of these distinct subclasses.
Methods
NPC tissue collection. All NPC tumours were collected by endoscopy or surgery.
Patient consent was obtained according to institutional clinical research approval
(IRB) at the Chinese University of Hong Kong, Hong Kong (for Asian cases), and
at the University of Pittsburgh, USA (for US cases). The original clinical and
survival data of patients were provided in Supplementary Data set.
Exome sequencing and variant calling. DNA was extracted from microdissected
FFPE or frozen tissue samples using the Qiagen FFPE DNA extraction kit as per
the manufacturer’s protocol. Solution based hybrid capture with the Agilent Sure-
Select method was followed by sequencing on the Illumina Hi-Seq instrument to a
goal coverage of 80 as previously described4. Raw FASTQ ﬁles were processed for
downstream analysis using PicardTools (http://broadinstitute.github.io/picard/).
BAM ﬁles are deposited to dbGAP-NHGRI (Study ID: 20055, Nasopharynx Cancer
Whole-Exome Sequencing) for public use.
Variant calling (SNVs, indels) was performed using the Firehose pipeline
running Mutect27, then ﬁltering out OxoG artifacts and likely germline mutations
that were previously seen in both dbSNP build 134 and 1,000 Genome data. To
remove potential artifacts from FFPE samples, we ﬁltered out variants in a variant
frequency peak with o5% frequency and total coverage under 30 . The overall
mutation rate and average coverage were calculated for the 105 tumour and normal
pairs. Signiﬁcance analysis was conducted using a local version of MutsigCV 2.0,
which considers gene expression, replication time and chromatin state when
calculating the background rate. To further improve our conﬁdence in the most
signiﬁcantly mutated genes, we also called mutations using Strelka28 and ﬁltered
out genes for whicho25% of mutations overlapped between the two methods. To
assess for the most likely cancer-associated mutations, we chose mutations seen in
at least three samples in the COSMIC database using Oncotator (10.1002/
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humu.22771). Germline variants identiﬁed from NPC patients were shown in
Supplementary Data 8. We used the Fluidigm Access Array microﬂuidic system,
which allows for multiplexed, high-throughput, amplicon sequencing using custom
targeted primers for a total of 464 positions to validate a total of 82% of variants
(Supplementary Data 9). These variants included both SNVs and indels in the cases
with minimum original allele frequencies of 15%. Copy number analysis was
performed using the ReCapseg, which calls and segments targeted genome data,
using panel of normals to model noise and normalize calls. Oncotator was used to
annotate genes affected by the CNVs. Signiﬁcantly recurring CNVs were
determined by putting the CNV segments into GISTIC 2.0 with mostly standard
settings, except for 0.6 as the ampliﬁcation and deletion threshold due to our
samples being microdissected, and join segment size of 10 and q value threshold
of 0.01 to reduce noise. Somatic rearrangements were detected using dRanger23,
using a score cutoff of 3. Mutational signature analysis was conducted using the
SomaticSignatures package in R (10.1093/bioinformatics/btv408) to identify the
mutation spectrum, and assess the number of signatures using non-negative matrix
factorization method. From simulating 2 to 10 signatures, we found the best-ﬁt
model consisted of four signatures, with the lowest standard error and describing
77% of variance. These signatures were correlated to known mutational processes
from the COSMIC database (version 8.12.2015.txt) using Pearson’s correlation
coefﬁcient. As we increased our model to more than four signatures, we did not
identify any additional highly correlated COSMIC signatures.
Whole-genome sequencing. For the 15 NPC cases that were subjected for
WGS, 1mg of genomic DNA extracted from the microdissected frozen tumours
and matched normal samples were subjected to the Illumina Whole-Genome
Sequencing Service in Macrogen (Seoul, Korea). Standard Illumina protocols and
Illumina paired-end adapters were used for library preparation from the fragmented
genomic DNA. Sequencing libraries were constructed with 500 bp insert length. WGS
was performed using the Illumina HiSeq 2000 platform with a standard 100-bp
paired-end read previously described29. Mean target coverage of 40 and 60 was
achieved for the normal and tumour samples, respectively. The raw sequence reads
were processed and aligned to the hg19 human reference genome using Isaac
aligner30. BAM ﬁles are deposited European Nucleotide Archive (ENA) (Accession
number PRJEB12830, WGS of matched normal and tumour samples of NPC
patients). Identiﬁcation of somatic SNV and SV was conducted by MuTect27 and
Manta31, respectively. To evaluate the sensitivity of somatic SV results, we used only
one SV result when different calls share breakpoints within 1,000 base pairs. We
predicted somatic copy number aberration and loss of heterozygosity in NPC genome
using TITAN32. Germline heterozygous SNVs of normal sample and the tumour read
counts of those sites were extracted by samtools/bcftools33. The identiﬁed somatic
copy number aberrations and SVs of each NPC were visualized by CIRCOS34.
Pathway diagram for NPC. To calculate recurrent percentages, we considered an
alteration to be activating if it landed in a known oncogene and was either a
COSMIC mutation (in at least three samples) or highly ampliﬁed. Similarly, we
considered alterations to be inactivating if they were nonsense or frameshift or
COSMIC mutations or homozygous deletions. Highly recurrent single copy gains
or losses were considered potentially activating or inactivating, respectively.
Missense or other nonsynonymous mutations were taken into consideration as
unknown functional effect.
Fluorescence in situ hybridization. FISH analysis was conducted to detect the
CYLD, TRAF3 and NFKBIA in FFPE NPC tissue sections. Commercially available
dual-colour (orange and green) ﬂanking probes of CYLD, TRAF3 and NFKBIA
were used (Empire Genomics, USA). FISH analysis was performed as we previously
described35. In each case, at least 100 nuclei were analysed. The break-apart signals
were scored if orange and green signals separated by one signal diameter or only
single signal were detected. Cases with translocation of CYTD, TRAF3 and NFKBIA
were deﬁned as 420% of breakapart signals in the tumour cells.
LMP1 immunohistochemical staining. The expression of LMP1 was determined
in FFPE NPC sections by immunohistochemical staining. After de-waxing, the
sections were subjected to antigen retrieval and staining in the automated slide
processing system BenchMark XT (Ventana Medical systems Inc., Tucson, AZ)
with the OptiView Ampliﬁcation kit (Ventana Medical Systems Inc.). The primary
antibody used in this study was anti-LMP1 mouse monoclonal antibody (CS.1-4,
Dako). The LMP1 expression was assessed by assigning a proportion score and an
intensity score36. The proportion score was according to the percentage of tumour
cells with positive membrane and cytoplasmic staining (0–100). The intensity score
was assigned for the average intensity of positive tumour cells (0, none; 1, weak;
2, intermediate; 3, strong). The LMP1 staining score was the product of proportion
and intensity scores, ranging from 0 to 300. The LMP1 expression was categorized
into absence/low (score 0–100) and high (score 101–300).
Immunoblotting. Immunoblotting was performed as previously published37.
All antibodies used were from Cell Signaling Technologies, USA. These are
antibodies against CYLD (#12797) and actin (#8456).
Generation of CYLD mutant cells. The CYLD wild-type (WT), and various CYLD
mutants were generated by gene synthesis and cloned into the pMXs-puro
vector (Cell Biolabs, USA). The pMXs-puro-EGFP plasmid was used as control.
The retroviral packaging cell line, Plat A cells were used to generate infective
retroviruses for C666-1 and HK1-EBV infection according to the manufacturer’s
instructions. Seven days after infection, cells were collected for the conﬁrmation of
CYLD mutant expression by immunoblotting. For growth assay, cells were plated
at low density (1 104 per well) in RPMI (for C666-1) or DMEM (for HK1-EBV)
with 4% FBS and assessed for proliferation at 48 h. Mutant-induced cell growth,
compared with the EGFP vector control or CYLDWT, was analysed by MTT assay.
C666-1 and HK1-EBV cell lines were previously established and authenticated in
our laboratory. No mycoplasma contamination was detected in these cell lines. An
uncropped images of western blot membranes for the expression of CYLD WT and
mutant protein is shown in Supplementary Fig. 15.
Soft agar colony formation assay. C666-1 stable cells expressing the CYLD WT
and various CYLD mutants were plated at a density of 1 105 cells per well of a 6-
well plate. Cells were grown in 0.35% soft agar for 21–24 days. Colonies were then
stained with 0.1% indonitrotetrazolium chloride (Sigma-Aldrich, USA) for 48 h,
and counted under a stereomicroscope.
Luciferase assay. C666-1 cells were co-transfected with CYLD WT or various
CYLD mutants with Cignal NF-kB Pathway Reporter Assay (Qiagen, USA). After
48 h, luciferase activity was measured using the Dual-Luciferase Reporter Assay
(Promega, USA). Luciferase counts were normalized to Renilia counts for each
sample.
Immunoﬂuorescence staining for Bcl-3 translocation. C666-1 cells were
transient transfected with the plasmid constructs expressing either the HA-tagged
CYLD WT or various CYLD mutants. At 48 h post-transfection, cells were ﬁxed
with 4% paraformaldehyde in PBS for 10min. Cells were then permeabilized and
blocked with blocking buffer (3% BSA, 0.1% Triton X-100 in PBS). After washing
with PBS, cells were incubated with the corresponding primary antibodies
(Anti-HA.11, 1:1,000 from BioLegend, USA; Anti-Bcl3 (C-14), 1:400 from Santa
Cruz, USA), and then in ﬂuorophore-conjugated secondary antibodies (Alexa
Fluor 488 and Alexa Fluor 555 from Invitrogen, USA). Cells were ﬁnally washed
with PBS and counterstained with 4,6-diamidino-2-phenylindole to label the
nuclei. The ﬂuorescence images of cells were captured with the Axio Observer
microscope (Zeiss) equipped with a cooled CCD (charge-coupled device) camera.
In vivo ubiquitination assay. HeLa cells were transfected with various CYLD-
expressing plasmids as indicated. Cells were harvested at 24 h post-transfection and
total protein extract was extracted with RIPA buffer supplemented with protease
inhibitors. Cell lysate was then boiled for 30min in RIPA buffer containing 1% SDS
to disrupt protein-protein interaction. The cell lysate was then cooled down on ice
and further diluted with RIPA buffer to decrease the SDS concentration to 0.1%
before performing immunoprecipitation. One milligram of protein lysate was
incubated with 1 mg anti-FLAG (M2) antibody from Sigma-Aldrich overnight at
4 C with constant rocking. Protein G-conjugated Dynabeads (Novex, Invitrogen)
was then added to pull-down the protein-containing antibody complex. The beads
were washed with RIPA buffer three times and incubated in 2 Laemmli buffer at
70 C for 10min to dissociate the Protein–antibody complex. The protein samples
were then separated by SDS–polyacrylamide gel electrophoresis and western
blotting was performed using the antibodies as indicated. The His-tagged K48R
ubiquitin plasmid was a kind gift from Dr Ramin Massoumi (Lund University,
Sweden).
Statistical analysis. Statistical analyses to test for correlation between genomic
and clinical features such as age, sex and clinical staging were performed using
standard R packages. We used the Fisher’s exact test for discrete variables, the
Log-rank test for continuous variables, and the Bonferonni method of multiple
testing correction.
Data availability. The WES and WGS data that support the ﬁndings of this study
have been deposited in dbGAP-NHGRI (Study ID: 20055, Nasopharynx Cancer
Whole-Exome Sequencing) and European Nucleotide Archive (ENA) (Accession
number PRJEB12830), respectively. All remaining data are included in the
manuscript and Supplementary Informations or available from the authors upon
request.
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